Moreover, the potential of HSP90 inhibitors to treat other diseases remains to be comprehensively explored, and recent research suggests that there are exciting opportunities, such as in Alzheimer disease (Inda et al., 2020), where the PU-AD has recently entered phase 1 clinical trials (NCT03935568), or in coronavirus infections, where ganetespib (ADX-1612) has recently entered phase 1 evaluation (https://www.aldeyra.com/pipeline-disease-areas/). This evidence concerns the gene HSP90AB1 and Alzheimer disease.